Head-To-Head Comparison: Cyclacel Pharmaceuticals (NASDAQ:BGMS) versus Ryerson (NYSE:RYZ)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Ryerson (NYSE:RYZ) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Valuation and Earnings

This table compares Cyclacel Pharmaceuticals and Ryerson”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750,000.00	6.51	-$3.00 million	($3.64)	-0.24
Ryerson	$5.84 billion	0.22	-$56.40 million	($1.24)	-19.75

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Ryerson. Ryerson is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Ryerson has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Cyclacel Pharmaceuticals and Ryerson, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Ryerson	2	1	0	0	1.33

Profitability

This table compares Cyclacel Pharmaceuticals and Ryerson’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
Ryerson	-0.56%	-0.62%	-0.21%

Institutional and Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.8% of Ryerson shares are owned by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 6.6% of Ryerson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Ryerson beats Cyclacel Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Ryerson

Ryerson Holding Corporation, together with its subsidiaries, processes and distributes industrial metals in the United States, Canada, Mexico, and China. It offers a line of products in carbon steel, stainless steel, alloy steels, and aluminum, as well as nickel and red metals in various shapes and forms, including coils, sheets, rounds, hexagons, square and flat bars, plates, structural, and tubing. The company also provides various processing services, such as bending, beveling, blanking, blasting, burning, cutting-to-length, drilling, embossing, flattening, forming, grinding, laser cutting, machining, notching, painting, perforating, polishing, punching, rolling, sawing, scribing, shearing, slitting, stamping, tapping, threading, welding, or other techniques to process materials. It serves various industries, including commercial ground transportation, metal fabrication and machine shops, industrial machinery and equipment manufacturing, consumer durable equipment, HVAC manufacturing, construction equipment manufacturing, food processing and agricultural equipment manufacturing, and oil and gas. The company was founded in 1842 and is headquartered in Chicago, Illinois.